Derivatives of 5-aminolevulinic acid for photodynamic therapy: enzymatic conversion into protoporphyrin.
In recent years, 5-aminolevulinic acid (ALA) has become a widespread agent for photodynamic therapy (PDT). In nucleated cells, ALA is converted into the endogenous photosensitizer protoporphyrin IX (PpIX). A major drawback of ALA is its low bioavailability. As a result, high doses of ALA must be administered in order to reach clinically relevant levels of PpIX. Moreover, only superficially located lesions can be treated as a result of the poor penetration of ALA into tissues. A possible solution for this problem may be provided by the prodrug concept. In the present study, prodrugs of ALA have been synthesized. These ALA prodrugs are shown to result in higher PpIX levels in cells than does ALA itself. Of a range of ester prodrugs of ALA, the ALA-pentyl ester elicits the highest fluorescence. Furthermore, the enzymatic conversion of the derivatives into ALA and PpIX has been studied in lysed cells. Under these circumstances, the esters with the shorter alkyl chains induce the highest fluorescence. The alcohols that arise as side products from enzymatic conversion of the prodrugs are shown to have no influence on the experiments.
Kloek
J
J
Department of Medicinal Photochemistry, Leiden/Amsterdam Center for Drug Research, Leiden University, The Netherlands. j.kloek@far.ruu.nl
Akkermans
W
W
Beijersbergen van Henegouwen
G M
GM
D000622:Aminolevulinic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D006868:Hydrolysis; D010778:Photochemotherapy; D011355:Prodrugs / Q000378:metabolism*; D011524:Protoporphyrins / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D011355:Prodrugs; D011524:Protoporphyrins; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX